---
document_datetime: 2026-02-06 10:21:52
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/retsevmo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: retsevmo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 7.1913949
conversion_datetime: 2026-02-09 22:09:29.793752
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.1
  docling: 2.72.0
  docling-core: 2.63.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Retsevmo

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber      | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|------------------------|------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation type IA_IN / | E.4Changeinthenameand/or addressof | 05/02/2026                          |                                          | SmPC,                           |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000315499                     | themarketingTermname:E.4 authorisation holder, ASMF holder, storage site of the master and/or working cell bank, manufacturing site for an active substance, intermediate or finished product, primary and/or secondary packaging site, manufacturer responsible for batch release, site where quality control takes place, and/or supplier of a packaging component, medical device (part), starting material, reagent and/orexcipient(whenmentioned in the dossier - E.4.a) The change in the name and/or address concerns the marketing authorisationholder-Accepted   |            |            | Labelling and PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Renewal - 1 year / EMA/R/0000286890   | Renewal of conditional marketing authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 16/10/2025 | 12/12/2025 | SmPC and Annex II  | TheCHMP,havingreviewedtheavailable informationonthestatusofthefulfilmentof SpecificObligationsandhavingconfirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstratedandthereforerecommendsthe renewaloftheconditional MAforRetsevmo,subject to theSpecificObligations andConditions aslaid down inAnnexIItotheopinion.Section5.1of the SmPChavebeenrevisedtoreflecttheupdated efficacydataavailablefromLIBRETTO-001study withdatacut-offof14February2025. |
| Variation type IA / EMA/VR/0000312896 | B.II.d.2Changeintestprocedurefor the finished product - B.II.d.2.a Minor changes to an approved test procedure -Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 18/11/2025 |            |                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| PSUR/EMA/PSUR/0000248503              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |      | Basedon thePRACreviewofdataonsafety and efficacy,thePRACconsidersthattherisk-benefit balance of medicinal products containing selpercatinibremainsunchangedandtherefore recommends the maintenance of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                 |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation typeIA/ EMA/VR/0000278785   | A.5Change in thename and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites)-A.5.b The activities for which the manufacturer/importer is responsibledonotincludebatchrelease- Accepted                                                                                                                                                                                                                                                                                                                             | 08/09/2025 |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Variation type II / EMA/VR/0000247142 | C.1.3 Change(s) in the Summary of Product Characteristics,LabellingorPackageLeaflet of human medicinal products intended to implementtheoutcomeofaprocedure concerningPSURorPASS,ortheoutcomeof theassessmentdonebythecompetent authority under Articles 45 or 46 of Regulation 1901/2006 - C.I.3.b Implementationof change(s)whichrequire tobefurthersubstantiatedbynewadditional datatobesubmittedbytheMAH-Accepted Updateofsection5.3of theSmPCinorder toupdateinformationon carcinogenesis based on results from a non-clinical 2-year carcinogenicity study ofselpercatinibinrats. | 10/04/2025 | 12/12/2025 | SmPC | Section5.3Long-termstudiesto assessthe carcinogenic potential of selpercatinib have not beenperformed.Ina2-yearcarcinogenicitystudy of selpercatinib in rats, vaginal tumours were observed insomefemalesatplasmaexposurelevelssimilar tolevelsobservedin adultpatientstreatedwith the dose of 160 mg twice daily. No pre-neoplastic changeswereobserved in thereproductivetractof femalerats.The clinical relevance of thesefindings is unknown.Selpercatinibwasnot carcinogenicin male rats in this study.Selpercatinibwas not carcinogenicinmaleandfemalemice ina6-month study. |

<div style=\"page-break-after: always\"></div>

| The RMP version 14.2 has also been submitted.   |
|-------------------------------------------------|